Deep Serratus Anterior Plane Block vs Surgically-placed Paravertebral Block for VATS Surgery (SAPB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03768193|
Recruitment Status : Completed
First Posted : December 7, 2018
Last Update Posted : December 7, 2018
Thoracic surgery, and surgery involving the chest wall in general, is associated with poorly controlled acute pain, which may result in delayed functional recovery, and may progress to chronic pain. Multimodal opioid-sparing analgesia regimens are a key component of the thoracic surgery enhanced recovery pathway, the aim of which is to improve outcomes in patients undergoing both minimally invasive and open thoracic surgical procedures. Novel interfascial plane blocks are emerging as feasible alternatives to central neuraxial analgesia techniques in a variety of clinical settings.
The aim of this study is to show non-inferiority of serratus anterior blockade compared with surgically placed paravertebral blocks in the management of perioperative acute pain in patients undergoing VATS procedures.
|Condition or disease||Intervention/treatment||Phase|
|Thoracic Diseases Thoracic Surgery Rib Fractures Pain, Postoperative Pain, Procedural Anaesthesia, Regional||Procedure: Deep serratus anterior plane block Procedure: Surgically-placed paravertebral block||Not Applicable|
Post-thoracotomy pain syndrome is an unwanted complication of thoracic surgery. Poorly controlled pain may precipitate increased morbidity in the immediate and early postoperative periods due to its adverse effects on respiratory mechanics and mobilisation, which may result in further morbidity such as postoperative pulmonary complications and thrombosis. Poor perioperative management of this pain may also result in the development of chronic pain. Enhanced recovery, particularly functional recovery has become an important goal in the perioperative management of our patients. A key principle of this pathway is multimodal opioid-sparing analgesia to facilitate improved recovery and patient outcomes. Regional anaesthesia forms the cornerstone of this multimodal analgesia regimen.
Traditionally, thoracic epidural and thoracic paravertebral blockade have been the main forms of regional anaesthesia utilised in thoracic surgical patients undergoing lung resection. With the increasing use of minimally invasive thoracic surgery and with a cohort of patients who may not always be suitable for central neuraxial blockade, alternatives are needed. More recently, there has been an emerging use of interfascial plane blocks in this patient group. The interest in these techniques is derived from case reports, case series, cadaveric studies, and small clinical trials, which have demonstrated clinical efficacy in a variety of elective and emergency thoracic surgical procedures and also in chronic thoracic pain syndromes.
The deep serratus anterior plane (deep SAP) block is a relatively new interfascial plane regional anaesthesia technique, which has been postulated to provide analgesia of the entire hemithorax. The mechanism of its analgesic effects are believed to occur via blockade of the lateral cutaneous branches of the thoracic intercostal nerves (T2-T12), which produces analgesia of the anterolateral chest wall. A recent anatomical study by Mayes et al. demonstrated consistent blockade of the lateral cutaneous branches of the intercostal nerves. Clinical studies, although small, have shown dermatomal spread in the T2 - T9 distribution of the anterolateral chest wall. Therefore, this block presents a potential alternative to central neuraxial blockade.
However, whether SAP blockade can produce non-inferior analgesia compared with either thoracic epidural or thoracic paravertebral, both in terms of somatic +/- autonomic blockade, and the reliability of dermatomal spread, has been questioned by some.
The aim of this randomised controlled trial is to demonstrate non-inferiority of ultrasound-guided continuous deep serratus anterior plane blockade compared with surgically-placed continuous paravertebral blockade, for perioperative analgesia, in the patients undergoing minimally-invasive videoscopic thoracic surgery.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Comparison of Ultrasound-guided Continuous Serratus Anterior Plane Blockade With Continuous Thoracic Paravertebral Blockade for Perioperative Analgesia Following Video-assisted Thoracoscopic Surgery (VATS)|
|Actual Study Start Date :||October 4, 2017|
|Actual Primary Completion Date :||September 1, 2018|
|Actual Study Completion Date :||September 1, 2018|
Experimental: Deep serratus anterior plane block
Ultrasound-guided deposition of 40mls of 2mg/ kg levobupivacaine into the deep serratus anterior plane space, in the mid axillary line, at the level of the 4th/5th rib. Insertion of a continuous local anaesthetic infusion catheter(Portex™) and continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
Procedure: Deep serratus anterior plane block
Deposition of local anaesthetic in the space between the serratus anterior muscle and the external intercostal muscle, at the level of the 4th-5th rib, in the midaxillary line. Procedure performed under ultrasound guidance. Catheter - based infusion of local anaesthetic into this space for 48 hours.
Active Comparator: Surgically-placed paravertebral block
Surgical placement of paravertebral local anaesthetic infusion catheters (Portex™) prior to closure. Bolus of levobupivacaine as per protocol. Continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
Procedure: Surgically-placed paravertebral block
Surgically-placed paravertebral block catheters for continuous local anaesthetic infusion of 0.125% levobupivacaine at 8-12mls/ hr for 48 hours.
- Opioid consumption [ Time Frame: Over the first 48 hours postoperatively ]Expressed as oral morphine equivalent
- Postoperative numerical pain scores [ Time Frame: Over the first 48 hours postoperatively ]Numerical rating scale. 0 - 10. 0=no pain, 1-3=mild pain, 4-6=moderate pain, 7-10=severe pain.
- Opioid side - effects - 1 [ Time Frame: Over the first 48 hours postoperatively ]Sedation scale. 0 = wide awake, 1 = drowsy but responds to normal verbal communication, 2 = asleep, but awakes with verbal communication. 3 = asleep, awakens with mild physical stimulation. 4 = asleep, unresponsive to physical stimulation.
- Opioid side - effects - 2 [ Time Frame: Over the first 48 hours postoperatively ]Nausea/ vomiting scale. Questionnaire. 0= none, 1=mild, 2=moderate, 3=severe
- Opioid side - effects - 3 [ Time Frame: Over the first 48 hours postoperatively ]Itch/ Pruritis scale 0= none, 1=mild, 2=moderate, 3=severe
- Mean arterial blood pressure [ Time Frame: Over the first 48 hours postoperatively. ]Calculated from systolic and diastolic blood pressure.
- Presence of dermatomal sensory block distribution [ Time Frame: Within the first 24 hours postoperatively ]Dermatomal sensory block distribution
- Functional assessment [ Time Frame: Within the first 48 hours postoperatively ]Walking distance in meters assessed by physiotherapist
- Patient satisfaction [ Time Frame: Over the first 48 hours postoperatively ]Subjective patient satisfaction scale. Subjective scale assessing Level of overall patient satisfaction with perioperative analgesia. Patient rates their experience as either 1 = insufficient, 2 = sufficient, 3 = very good, 4 =excellent.
- Duration of inpatient hospital admission [ Time Frame: From date of admission for surgery to date of discharge by the thoracic team; through to study completion. ]Measured in days.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03768193
|Mater Misericordiae University Hospital|
|Dublin, Ireland, Dublin 7|
|Principal Investigator:||Conor Hearty, FFPMCAI,FFPMANZCA,FCARCSI,FIPP||Consultant Anaesthetist, Mater Misericordiae University Hospital|